Coherus Oncology (CHRS) Q3 2026 earnings summary

Executive summary

• Strategic plan prioritizes tagmokitug plus toripalimab in esophageal cancer, deprioritizes other indications, and reduces headcount by ~30%.

• LOQTORZI demand continued to grow; management aims to increase NPC market share and move toward financial self-sufficiency, with core cash-burn break-even targeted in 2027.

• Right-sizing and potential ex-U.S. partnering are intended to support development and a financially sustainable oncology business.

Financial highlights

• Q3 continuing-operations revenue was $14.274M vs. $11.571M YoY; 9M revenue was $40.891M vs. $29.424M, primarily on LOQTORZI volume growth.

• Q3 LOQTORZI revenue was $14.009M, up 25% YoY and 3% QoQ; sequential growth was below the 10%-15% target amid slower new patient starts in select territories.

• Q3 GAAP net loss from continuing operations was $38.875M, or $(0.25) per diluted share, vs. $44.5M and $(0.38) YoY; Q3 non-GAAP continuing-operations net loss was $31.2M.

• Q3 R&D expense fell to $22.6M from $27.3M YoY; SG&A fell to $21.2M from $24.9M.

• Q3 operating cash use was $34.0M, 43% below the H1 2026 quarterly average; 9M operating cash use was $153.995M.

Outlook and guidance

• 2026 LOQTORZI revenue outlook was revised to $54M-$57M, with Q4 sales of $15M expected; FY2026 combined OpEx guidance was reiterated at $170M-$175M.

• Cost actions are expected to save $6M-$7M per quarter, mostly within two quarters, reducing quarterly LOQTORZI revenue needed to cover core costs to $25M-$30M from $30M-$35M.

• FDA alignment on tagmokitug dose and an expedited esophageal-cancer development path is planned for early 2027; a randomized study versus chemotherapy and potential accelerated approval based on ORR and six-month duration are under consideration.

• First data from the randomized Phase 2 casdozokitug/toripalimab/bevacizumab study in first-line uHCC are expected in 1H 2027.